Published by TMR Research Insights
Posted on October 6, 2021
5 min readLast updated: January 31, 2026
The AML biomarker testing market is set for growth from 2020 to 2030 due to rising leukemia cases and an aging population, with North America leading the market.
The acute myeloid leukemia (AML) biomarker testing market is anticipated to gain promising growth across the tenure of 2020-2030. The rising incidence of acute myeloid leukemia (AML), a type of cancer is the prime factor for expansive growth. The geriatric population is also at an all time high across the globe. This factor will have a positive effect on the growth of the acute myeloid leukemia (AML) biomarker testing market.
For More Industry Insight, Request Brochure@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=80658
The American Cancer Society predicts about 19,940 new cases of acute myeloid leukemia (AML) will emerge and about 11,980 deaths will be observed in the United States. These alarming statistics reveal the seriousness of the effect of the disease. Thus, the rising concern about the growing incidences will lay a red carpet of growth across the acute myeloid leukemia (AML) biomarker testing market.
On the basis of type, the acute myeloid leukemia (AML) biomarker testing market can be segmented into genetic acute myeloid leukemia (AML) biomarker (MU-AML, FLT3, TP53, NPM1, and others), proteomic acute myeloid leukemia (AML) biomarker (HSP, CALR, HNRH1, and FIBA), and epigenetic acute myeloid leukemia (AML) biomarker (DNMT3A, IDH1/2, and TET).
The increasing utilization of acute myeloid leukemia (AML) biomarker testing across academic research institutes, hospitals, and others may further strengthen the growth prospects of the acute myeloid leukemia (AML) biomarker testing market.
The study on the acute myeloid leukemia (AML) biomarker testing market helps the CXOs to bury the barriers of fake information and offers a full analysis of varied segments. The report offers a five-point (emerging trends, competitive landscape, a scrutinized detail of the regions, key players, and latest developments) benefit to the stakeholder. This factor plays an important part in imparting the right information to the stakeholder.
Furthermore, the study pays attention to the effect of the SARS-CoV-2 pandemic and also on the dangers that may hurt the growth of the acute myeloid leukemia (AML) biomarker testing market. The analysis by the researchers also highlights the opportunities and challenges that the acute myeloid leukemia (AML) biomarker testing market is anticipated to face between 2020 and 2030.
The acute myeloid leukemia (AML) biomarker testing market is extensively fragmented with a varied range of players in the ring for obtaining a prominent position among others. The players in the acute myeloid leukemia (AML) biomarker testing market are involved in intense research and development activities, leading to discovery of novel insights that strengthen the diagnosis to a great extent.
Some key players in the acute myeloid leukemia (AML) biomarker testing market are Novartis AG, Sysmex Corporation, Skyline DX B.V., Abbott Laboratories, Cancer Genetics Inc., bioMérieux SA, Cancer Genetics Inc., and Epigenomics AG.
Quick diagnosis is important for detecting and treating this type of cancer. Hence, this factor invites considerable growth prospects for the acute myeloid leukemia (AML) biomarker testing market. The acute myeloid leukemia (AML) biomarker testing technique helps in identifying this type of cancer and also assists in prognosis and monitoring. Thus, all these benefits bode well for the growth of the acute myeloid leukemia (AML) biomarker testing market.
North America’s acute myeloid leukemia (AML) biomarker testing market may acquire a dominant place in terms of regional contribution. The heightening cases of cancer across the region may prove to be a major growth factor. Asia Pacific may also gain substantial growth for the acute myeloid leukemia (AML) biomarker testing market during the assessment period. The rising expenditure on healthcare infrastructure may invite exponential growth.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers’ or customers’ journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Get Exclusive PDF Sample Copy Of This Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=80658
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
The article discusses the growth and trends in the AML biomarker testing market from 2020 to 2030.
The rising incidence of AML and an increasing geriatric population are key growth drivers.
Notable companies include Novartis AG, Sysmex Corporation, and Abbott Laboratories.
Explore more articles in the Research Reports category
